

Product Datasheet

CCR4 antibody (orb613910)

Evolution Bioprecipitants.
Description

Rabbit monoclonal antibody to CCR4

Species/Host

Human

Reactivity

Human

Conjugation

Unconjugated

Tested Applications

Depletion

Immunogen

This antibody was prepared by humanization of a mouse anti-CCR4 mAb.

Target

CCR4

Preservatives

PBS with 0.02% Proclin 300.

Concentration

1 mg/ml

Storage

Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Note

For research use only

Application notes

The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Biorbyt has not been de-fucosylated.

Isotype

IgG

Clonality

Monoclonal

Purity

Purified